iTTP treatment characteristics according to age
| . | Age <60 y, n = 340 . | Age ≥60 y, n = 71 . | P . |
|---|---|---|---|
| Initial management | |||
| Time from hospital admission to diagnosis, d | 1 [1; 3]* | 3 [1; 7]† | .0001 |
| Time from diagnosis to treatment, d | 0 [0; 1]* | 0 [0; 1]† | .062 |
| Corticosteroids therapy | 285 (84) | 55 (77) | .22 |
| Total plasma exchange volume, mL/kg | 541 [289; 1001] | 412 [256; 1010] | .20 |
| Second-line management | |||
| Exacerbation or refractory TTP | 200 (62)‡ | 35 (63)§ | 1.00 |
| Cyclophosphamide | 17 (5) | 4 (6) | .77 |
| Rituximab | 179 (53) | 31 (44) | .37 |
| No. of infusions | 4 [3; 4] | 3 [1; 4] | .033 |
| Vincristine | 20 (6) | 5 (7) | .78 |
| Splenectomy | 9 (3) | 1 (1) | 1.00 |
| Platelet transfusion | 126 (37) | 19 (27) | .10 |
| Adverse events | |||
| Lethal catheter-related adverse events | 0 (0) | 1 (1) | .16 |
| Infection | 0 (0) | 1 (1) | .16 |
| Bleeding | 0 (0) | 1 (1) | .16 |
| Nonlethal catheter-related adverse events | 75 (23)|| | 22 (34)† | .055 |
| Infection | 45 (14)|| | 12 (18)† | .33 |
| Thrombosis | 38 (12)|| | 6 (9)† | .83 |
| Bleeding | 5 (2)|| | 2 (3)† | .32 |
| Accidental catheter self-removal/contention | 0 (0)|| | 9 (14)† | <.0001 |
| Plasma exchange–related adverse events | 60 (18)|| | 3 (5)† | .005 |
| Anaphylaxis | 38 (12)|| | 3 (5)† | .12 |
| Serum sickness | 1 (0.3)|| | 0 (0)† | 1.00 |
| Others | 22 (7)|| | 0 (0)† | .033 |
| . | Age <60 y, n = 340 . | Age ≥60 y, n = 71 . | P . |
|---|---|---|---|
| Initial management | |||
| Time from hospital admission to diagnosis, d | 1 [1; 3]* | 3 [1; 7]† | .0001 |
| Time from diagnosis to treatment, d | 0 [0; 1]* | 0 [0; 1]† | .062 |
| Corticosteroids therapy | 285 (84) | 55 (77) | .22 |
| Total plasma exchange volume, mL/kg | 541 [289; 1001] | 412 [256; 1010] | .20 |
| Second-line management | |||
| Exacerbation or refractory TTP | 200 (62)‡ | 35 (63)§ | 1.00 |
| Cyclophosphamide | 17 (5) | 4 (6) | .77 |
| Rituximab | 179 (53) | 31 (44) | .37 |
| No. of infusions | 4 [3; 4] | 3 [1; 4] | .033 |
| Vincristine | 20 (6) | 5 (7) | .78 |
| Splenectomy | 9 (3) | 1 (1) | 1.00 |
| Platelet transfusion | 126 (37) | 19 (27) | .10 |
| Adverse events | |||
| Lethal catheter-related adverse events | 0 (0) | 1 (1) | .16 |
| Infection | 0 (0) | 1 (1) | .16 |
| Bleeding | 0 (0) | 1 (1) | .16 |
| Nonlethal catheter-related adverse events | 75 (23)|| | 22 (34)† | .055 |
| Infection | 45 (14)|| | 12 (18)† | .33 |
| Thrombosis | 38 (12)|| | 6 (9)† | .83 |
| Bleeding | 5 (2)|| | 2 (3)† | .32 |
| Accidental catheter self-removal/contention | 0 (0)|| | 9 (14)† | <.0001 |
| Plasma exchange–related adverse events | 60 (18)|| | 3 (5)† | .005 |
| Anaphylaxis | 38 (12)|| | 3 (5)† | .12 |
| Serum sickness | 1 (0.3)|| | 0 (0)† | 1.00 |
| Others | 22 (7)|| | 0 (0)† | .033 |
Data were provided as median [interquartile range] and compared by use of the Mann-Whitney Wilcoxon rank-sum test. Categorical data were summarized as count (%) and compared by use of the χ2 or Fisher tests.
Data were available for 328 patients.
Data were available for 65 patients.
Data were available for 322 patients.
Data were available for 56 patients.
Data were available for 326 patients.